scispace - formally typeset
Search or ask a question
Author

Jianli Ma

Bio: Jianli Ma is an academic researcher from Chinese PLA General Hospital. The author has contributed to research in topics: Self-healing hydrogels & Drug delivery. The author has an hindex of 9, co-authored 12 publications receiving 585 citations.

Papers
More filters
Journal ArticleDOI
TL;DR: In vivo performances of drug nanocrystals exhibited in animals in different administration route were reviewed, and the advantages of drug Nanocrystals in the aspect of safety, pharmacodynamics, pharmacokinetics and targeting delivery were discussed in detail.

280 citations

Journal ArticleDOI
TL;DR: The in vivo performances of oral drug nanocrystals exhibited in animals related to the pharmacokinetic, efficacy and safety characteristics were described and the technologies and evaluation associated with the solidification process of the drug Nanocrystals suspensions were discussed in detail.
Abstract: The limited solubility and dissolution rate exhibited by poorly soluble drugs is major challenges in the pharmaceutical process. Following oral administration, the poorly soluble drugs generally show a low and erratic bioavailability which may lead to therapeutic failure. Pure drug nanocrystals, generated by “bottom up” or “top down” technologies, facilitate a significant improvement on dissolution behavior of poorly soluble drugs due to their enormous surface area, which in turn lead to substantial improvement in oral absorption. This is the most distinguished achievement of drug nanocrystals among their performances in various administration routes, reflected by the fact that most of the marketed products based on the nanocrystals technology are for oral application. After detailed investigations on various technologies associated with production of drug nanocrystals and their in vitro physicochemical properties, during the last decade more attentions have been paid into their in vivo behaviors. This review mainly describes the in vivo performances of oral drug nanocrystals exhibited in animals related to the pharmacokinetic, efficacy and safety characteristics. The technologies and evaluation associated with the solidification process of the drug nanocrystals suspensions were also discussed in detail.

175 citations

Journal ArticleDOI
TL;DR: The mucoadhesive polymers have enormous potential for the delivery of therapeutic macromolecules, genes, and vaccines through the nasal cavity with high drug bioavailability.
Abstract: Background: Over the last decades, the application of mucoadhesive polymers in nasal drug delivery systems has gained interest among pharmaceutical scientists as a means of promoting dosage form residence time in the nasal cavity as well as improving intimacy of contact with absorptive membranes of the biological system. In addition, the enhanced paracellular absorption following the swelling of the mucoadhesive polymers on the nasal membranes provides an important way for the absorption of the macromolecules through the nasal cavity. Method: This paper describes some aspects of mucoadhesion related to the nasal drug delivery system. First the theories of the adhesion of mucoadhesive polymers to the mucosa epithelium are described. Then the characteristics and application of several widely used polymers in nasal drug delivery are presented. Finally, the influences of dosage form on the nasal absorption of drugs in the mucoadhesive polymer-based formulations are discussed. Conclusion: The mucoadhesive poly...

51 citations

Journal ArticleDOI
TL;DR: The paclitaxel nanosuspensions prepared in this study could markedly enhance the tolerance dosage in mice, and manifest different pharmacokinetic properties compared with the solution.

36 citations

Journal ArticleDOI
TL;DR: The usage of TPGS as stabilizers on the surface of nanocrystals of insoluble anticancer drugs may be an effective approach to overcome the multi-drug resistances (MDR).

35 citations


Cited by
More filters
Journal Article
TL;DR: Expectations regarding nanodrugs that are in early stages of development or clinical trials need to remain realistic because of the need for better characterization and the lack of specific regulatory guidelines.
Abstract: Nanomedicine is a relatively new and rapidly evolving field combining nanotechnology with the biomedical and pharmaceutical sciences.1-3 Nanoparticles (NPs) can impart many pharmacokinetic, efficacy, safety, and targeting benefits when they are included in drug formulations.1-5 Many nanodrugs have entered clinical practice, and even more are being investigated in clinical trials for a wide variety of indications.2 However, nanopharmaceuticals also face challenges, such as the need for better characterization, possible toxicity issues, a lack of specific regulatory guidelines, cost-benefit considerations, and waning enthusiasm among some health care professionals. 4,5 For these reasons, expectations regarding nanodrugs that are in early stages of development or clinical trials need to remain realistic.4.

453 citations

Journal ArticleDOI
Kinam Park1
24 Sep 2013-ACS Nano
TL;DR: Nanoparticle approaches can have real impact in improving drug delivery by focusing on the problems at hand, such as enhancing their drug loading capacity, affinity to target cells, and spatiotemporal control of drug release.
Abstract: Nanotechnology in drug delivery has been manifested into nanoparticles that can have unique properties both in vitro and in vivo, especially in targeted drug delivery to tumors. Numerous nanoparticle formulations have been designed and tested to great effect in small animal models, but the translation of the small animal results to clinical success has been limited. Successful translation requires revisiting the meaning of nanotechnology in drug delivery, understanding the limitations of nanoparticles, identifying the misconceptions pervasive in the field, and facing inconvenient truths. Nanoparticle approaches can have real impact in improving drug delivery by focusing on the problems at hand, such as enhancing their drug loading capacity, affinity to target cells, and spatiotemporal control of drug release.

440 citations

Journal ArticleDOI
TL;DR: This review presents a comprehensive summary of the recent advances in carrier-assistant drug delivery systems for cancer therapy and emphatically discusses some representative achievements of these DSDSs for passive or/and positive targeting therapy, combinational therapy as well as theranostics.

396 citations

Journal ArticleDOI
TL;DR: This review will discuss unstable suspensions, methods and guidelines for selecting and optimizing stabilizers, approaches for enhancing stability, and other factors that influence nanosuspension stability.

332 citations

Journal ArticleDOI
TL;DR: N nanoparticle design aspects to improve delivery to particular sites in the GI tract are discussed and the state-of-the-art in preclinical targeted nanoparticles design is reviewed.

286 citations